Skip to main content

Advertisement

Table 5 Base case results

From: Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist

  EINSTEIN DVT EINSTEIN PE
  Rivaroxaban Dual LMWH/VKA therapy Incremental Rivaroxaban Dual LMWH/VKA therapy Incremental
Patients appropriate for 3 months of anticoagulation
Drug acquisition cost (£) 220 98 122 217 99 118
Other costs (£) 1592 1964 −372 4295 4808 −513
Total costs (£) 1812 2063 −251 4511 4907 −396
QALYs 13.286 13.264 0.022 11.940 11.912 0.027
ICER (£)    Rivaroxaban dominates    Rivaroxaban dominates
Patients appropriate for 6 months of anticoagulation
Drug acquisition cost (£) 398 104 295 393 105 288
Other costs (£) 1561 2040 −479 4153 4654 −501
Total costs (£) 1959 2143 −184 4546 4759 −213
QALYs 13.294 13.268 0.026 11.992 11.979 0.013
ICER (£)    Rivaroxaban dominates    Rivaroxaban dominates
Patients appropriate for 12 months of anticoagulation
Drug acquisition cost (£) 731 114 617 728 115 613
Other costs (£) 1512 2186 −673 4154 4900 −746
Total costs (£) 2243 2299 −56 4881 5015 −133
QALYs 13.308 13.274 0.034 12.035 12.015 0.020
ICER (£)    Rivaroxaban dominates    Rivaroxaban dominates
Patients appropriate for lifelong anticoagulation
Drug acquisition cost (£) 6566 288 6278 6025 284 5740
Other costs (£) 2084 6835 −4751 4532 9209 −4677
Total costs (£) 8649 7122 1527 10,557 9493 1064
QALYs 13.507 13.331 0.176 12.526 12.375 0.150
ICER (£)    8677    7072
  1. ICER, incremental cost-effectiveness ratio; LMWH, low molecular weight heparin; QALY, quality-adjusted life-year; VKA, vitamin K antagonist.